SCHEMBL1492035

SCHEMBL1492035

CCS(=O)(=O)N(Cc1ccc(OC)cc1)c1ccc(F)c(N)c1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APLNR P35414 4/20 0.43
CNR2 P34972 5/20 0.41
CNR1 P21554 3/20 0.40
TAS2R14 Q9NYV8 6/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ACLY P53396 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462111 0.94 APLNR (0.41) APLNRCNR2CNR1TAS2R14CA12
SCHEMBL1492094 0.89 CNR2 (0.44) APLNRCNR2CNR1TAS2R14NR3C1
SCHEMBL9930518 0.89 CNR2 (0.42) APLNRCNR2CNR1TAS2R14CA12
SCHEMBL12499269 0.87 APLNR (0.39) APLNRCNR2CNR1TAS2R14CA12
SCHEMBL12497894 0.85 APLNR (0.39) APLNRCNR2CNR1TAS2R14NR3C1
SCHEMBL1460926 0.84 CNR2 (0.40) APLNRCNR2CNR1TAS2R14CA12
SCHEMBL9930750 0.84 CNR2 (0.42) APLNRCNR2CNR1TAS2R14NR3C1
SCHEMBL9930946 0.79 ACHE (0.37) CNR2CA2NR3C1ALDH1A1ACLY
SCHEMBL12497941 0.78 CNR2 (0.39) APLNRCNR2CNR1TAS2R14NR3C1
SCHEMBL12826128 0.78 APLNR (0.37) APLNRCNR2CNR1TAS2R14CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102712646-A RAF inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC 2012-10-03 CN disclosed
EP-2470538-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-07-04 EP disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
WO-2011025940-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed
WO-2011025940-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF APLNR 4487/4885CNR2 4318/4885CNR1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.